SCHEMBL2952131

SCHEMBL2952131

CC1(C)OCC(C)(C(=O)NNC(=O)c2ccc(OCCCCc3ccccc3)c(C(F)(F)F)c2)N1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.37
PDE4B Q07343 2/20 0.37
PDE4C Q08493 2/20 0.37
PDE4D Q08499 2/20 0.37
S1PR1 P21453 2/20 0.36
CNR2 P34972 2/20 0.36
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
S1PR4 O95977 1/20 0.36
S1PR3 Q99500 1/20 0.36
S1PR5 Q9H228 1/20 0.36
MRGPRX4 Q96LA9 3/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RXRA P19793 2/20 0.35
RXRB P28702 2/20 0.35
RXRG P48443 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946699 0.99 S1PR1 (0.37) PDE4APDE4BPDE4CPDE4DS1PR1
SCHEMBL13238163 0.92 PPARG (0.35) PDE4APDE4BPDE4CPDE4DS1PR1
SCHEMBL3170139 0.91 RXRA (0.36) S1PR1PPARGPPARDRXRARXRB
SCHEMBL13238161 0.91 S1PR1 (0.35) PDE4APDE4BPDE4CPDE4DS1PR1
SCHEMBL2947000 0.91 RXRA (0.44) PPARGPPARDMRGPRX4RXRARXRB
SCHEMBL4018047 0.90 THRA (0.45) S1PR1CNR2PPARGPPARDPPARA
SCHEMBL1171971 0.90 THRA (0.47) S1PR1CNR2PPARGPPARDPPARA
SCHEMBL2955178 0.90 THRA (0.47) S1PR1CNR2PPARGPPARDPPARA
SCHEMBL2949250 0.89 THRA (0.41) PDE4APDE4BPDE4CPDE4DS1PR1
SCHEMBL3180727 0.87 THRA (0.43) S1PR1CNR2PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759370-B2 Sphingosine-1-phosphate (SIP) receptor agonists Praecis Pharmaceuticals (US) 2010-07-20 US disclosed
US-20100009936-A1 CHEMICAL COMPOUNDS PRAECIS PHARMACEUTICALS INCORPORATED (US) 2010-01-14 US disclosed
EP-2046746-A2 CHEMICAL COMPOUNDS Praecis Pharmaceuticals Incorporated (US) 2009-04-15 EP disclosed
US-20080096938-A1 Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example PRAECIS PHARMACEUTICALS INCORPORATED (US) 2008-04-24 US disclosed
WO-2008016692-A2 CHEMICAL COMPOUNDS PRAECIS PHARMACEUTICALS INCORPORATED (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096938-A1 Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example S1PR1, S1PR2, S1PR5 PDE4A 717/4885PDE4B 838/4885PDE4C 1005/4885
US-20100009936-A1 CHEMICAL COMPOUNDS CD4, ICOS, NFATC1 PDE4A 2189/4885PDE4B 1940/4885PDE4C 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.